S. Morris

Anti – HIV-1 Activity of Weekly or Biweekly Treatment with Subcutaneous PRO 140 , a CCR 5 Monoclonal Antibody

N. Stambler, M. Saag, A. Marozsan, 2010 .

A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer.

H. Scher, W. Olson, S. Slovin, 2013, Vaccine.

Phase 1 study of PSMA ADC, an antibody‐drug conjugate targeting prostate‐specific membrane antigen, in chemotherapy‐refractory prostate cancer

P. Kantoff, N. Stambler, D. Petrylak, 2019, The Prostate.

Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody.

N. Stambler, M. Saag, A. Marozsan, 2010, The Journal of infectious diseases.

Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults.

R. Redfield, C. Fichtenbaum, M. Saag, 2008, The Journal of infectious diseases.

Phase 2a Study of the CCR5 Monoclonal Antibody PRO 140 Administered Intravenously to HIV-Infected Adults

C. Fichtenbaum, N. Stambler, M. Saag, 2010, Antimicrobial Agents and Chemotherapy.

First-in-human phase I trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory prostate cancer.

P. Kantoff, D. Petrylak, W. Olson, 2010 .

Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in taxane-refractory prostate cancer.

P. Kantoff, D. Petrylak, W. Olson, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.